Case report: complete pathologic response to neoadjuvant ensartinib in locally advanced, ALK-positive lung squamous cell carcinoma - Top-Institutions - MDSpire

Case report: complete pathologic response to neoadjuvant ensartinib in locally advanced, ALK-positive lung squamous cell carcinoma

  • By

  • Yingyu Yang

  • Junkai Zhang

  • Zhirun Xie

  • Sirui Zhang

  • May 25, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

Original Source(s)

Case report: complete pathologic response to neoadjuvant ensartinib in locally advanced, ALK-positive lung squamous cell carcinoma

  • by Yingyu Yang, Junkai Zhang, Zhirun Xie, Sirui Zhang

  • May 25, 2026

Related Content

Real-world healthcare resource use and costs associated with the management of locally advanced head and neck cancer in Portugal – TRACE2 study

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?